retatrutide triple agonist obesity trial VisualAbstract: reduces body weight by 17.5% in patients with Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon

Results depend on individual health factors, program adherence, and clinical evaluation

This task fell to Lotte Bjerre Knudsen, a pharmaceutical scientist at Novo Nordisk

Because weight loss is not only about medication but also about lifestyle changes, some people may remain on Semaglutide longer under guidance

The effectiveness was superior to both monoagonists and dual agonists

We have clients from across New JerseyOcean County, Mercer County and Middlesex County

Acknowledgments Figures were created with the BioRender Software ( Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest